Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer

Oncologist

Volumn 17, Issue 2, 2012, Pages 164-171

  Hedden, Lindsay ^a,b,c   O'Reilly, Susan ^d   Lohrisch, Caroline ^b   Chia, Stephen ^b   Speers, Caroline ^b   Kovacic, Laurel ^b   Taylor, Suzanne ^e   Peacock, Stuart ^a,b,c  

^a Canadian Centre for Applied Research in Cancer Control   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d National Cancer Control Programme   (Ireland)

^e MINISTRY OF HEALTH   (Canada)

Author keywords

Antibodies; Breast neoplasms; Cost benefit analysis; Drug costs; Monoclonal

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; BREAST CANCER; CARDIOTOXICITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; FEMALE; HIDDEN MARKOV MODEL; HUMAN; LIFE YEAR GAINED; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RELAPSE; REVIEW; SENSITIVITY ANALYSIS;

EID: 84930480661     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0379     Document Type: Review

References (27)

1. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. STEMCELLS 1998;16:413-428.
2. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007;26:3637-3643.
3. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
6. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
7. Kurian AW, Thompson RN, Gaw AF et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007;25:634-641.
8. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007;25:625-633.
9. Norum J, Olsen JA, Wist EA et al. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol 2007;46: 153-164.
10. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
11. Wapnir IL, Anderson SJ, Mamounas EP et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol 2006;24: 2028-2037.
12. Bonadonna G, Moliterni A, Zambetti M et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005;330:217.
13. Cowper PA, DeLong ER, Whellan DJ et al. Economic effects of beta-blocker therapy in patients with heart failure. Am J Med 2004;116:104-111.
14. Earle CC, Chapman RH, Baker CS et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-3317.
15. Lewis EF, Johnson PA, Johnson W et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20:1016-1024.
16. Hutton J, Brown R, Borowitz M et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9(Suppl 2):8-22.
17. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 2003;23: 341-350.
18. Wai ES, Trevisan CH, Malfair Taylor SC et al. Health system costs of metastatic breast cancer. Breast Cancer Res Treat 2001;65:233-240.
19. Will BP, Petit CL, Berthelot JM et al. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Br J Cancer 1999;79:1428-1436.
20. Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997;36(Suppl 9):1-60.
21. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160-168.
22. Smith TJ, Hillner BE. The efficacy and costeffectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993;11:771-776.
23. Lidgren M, Wilking N, Jönsson B et al. Health related quality of life in different states of breast cancer. Qual Life Res 2007;16:1073-1081.
24. Launois R, Reboul-Matry J, Henry B. A costutility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996;10:504-521.
25. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 1992;267:2055-2061.
26. Clement FM, Harris A, Li JJ et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia and Canada. JAMA 2009;302:1437-1443.
27. Claxton K, Schulpher M, McCabe C et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339-347.